Ulcerative Colitis – Pipeline Review, 2019

Ulcerative colitis is a type of inflammatory bowel disease (IBD) where the colon or inner lining of the stomach becomes inflamed that results in the development of ulcers, or tiny open sores which could bleed and causes abdominal discomfort. Fatigue, loss of appetite, fever, diarrhea, rectal pain, and bleeding, etc. are some of the symptoms associated with ulcerative colitis. In 2015, according to the Centers for Disease Control and Prevention (CDC), it was estimated that 1.0 to 1.3 million people globally suffered from inflammatory bowel disease.

Anti-inflammatory drugs such as 5-aminosalicylic acid and corticosteroids are used as first-line therapy in the treatment of ulcerative colitis. Based on the severity of the symptoms, immunosuppressant drugs such as cyclosporine and azathioprine and biologics such as infliximab are used to treat ulcerative colitis. In addition, in most severe cases, surgical procedures such as ileal pouch-anal anastomosis are opted to treat ulcerative colitis.

Many pharmaceutical companies along with government research institutes have been focusing on studying and developing new treatment options for ulcerative colitis. For instance; RO7049665, which is being studied by F. Hoffmann-La Roche Ltd is currently in phase-1 clinical trials study for RO7049665 in Patients with Ulcerative Colitis (UC).

At present, around 63% of the pipeline candidates for ulcerative colitis are in the phase-2 and phase-4 stage. Majority of the studies have been conducted by industries and by government-funded organizations.

Report Description

The report on ‘Ulcerative Colitis – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Ulcerative Colitis. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Ulcerative Colitis.

The report on ‘Ulcerative Colitis – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• A thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target
• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
• Overview of dormant and discontinued pipeline products
• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
• Overview of the latest developments; news articles, press releases, and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
• Desk research sources include global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on a comprehensive overview of the R&D activity and pipeline products for Ulcerative colitis
• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
• Identify the focus of leading players in relation to R&D for Ulcerative colitis
• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business
• Analyze the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary